Icu Medical (ICUI) risk factors, FY2024 10-K

Market and Other External Risks

1. 01If we are unable to compete successfully with our competitors, we may be unable to maintain market share, in which case our sales may not grow and our profitability may be adversely affected
2. 02If demand for our products were to decline significantly, we might not be able to recover the cost of our expensive automated molding and assembly equipment and tooling, which could have an adverse effect on our financial condition and results of operations
3. 03Product development requires substantial investment that may be difficult for us to fund and may be challenging to recover through commercial product sales
4. 04If we do not successfully develop and commercialize enhanced or new products that remain competitive with new products or alternative technologies developed by others, we could lose revenue opportunities and customers, and our ability to grow our business would be impaired
5. 05Cost volatility or loss of supply of our raw materials could have an adverse effect on our profitability
6. 06If we cannot obtain additional custom tooling and equipment on a timely basis to enable us to meet demand for our products, we might be unable to increase our sales or might lose customers, in which case our sales could decline
7. 07Heightened inflation, higher interest rates and foreign currency rate fluctuations as a result of global macroeconomic and geopolitical conditions have had and could in the future have a material adverse effect on our operations
8. 08Our operating results may be adversely affected by unfavorable economic conditions that affect our customers’ ability to buy our products and our suppliers' demand for payment terms
9. 09Continuing pressures to reduce healthcare costs and inadequate coverage and reimbursement may adversely affect our prices. If we cannot reduce manufacturing costs of existing and new products to counteract such pricing pressures, our sales may not grow and our profitability may decline
10. 10Failure to protect our information technology systems against security breaches, service interruptions, or misappropriation of data could disrupt operations, compromise sensitive data, and expose us to liability, possibly causing our business and reputation to suffer
11. 11Our business could suffer if we lose the services of key personnel
12. 12The price of our common stock has been and may continue to be highly volatile due to many factors
13. 13Climate-related events and other events could harm our business
14. 14The increasing focus on sustainability and environmental, social and governance ("ESG") initiatives could increase our costs, harm our reputation and adversely impact our financial results

Business and Operating Risks

1. 15Damage to, or interruptions at, any of our manufacturing facilities or our suppliers' facilities could impair our ability to produce our products
2. 16We are dependent on single and limited source third-party suppliers, which subjects our business and results of operations to risks of supplier business interruptions, and a loss or degradation in performance in our suppliers could have an adverse effect on our business and financial condition
3. 17We may not be successful in achieving expected operating efficiencies or expense reductions associated with cost reduction and restructuring efforts and may experience a decline in our profitability, business disruptions or other adverse consequences to our business as a result
4. 18The agreements governing our debt contain a number of restrictive covenants which limit our flexibility in operating our business, finance future operations or pursue our business strategies
5. 19Significant sales through distributors expose us to risks that could have a material effect on our results of operations

Legal, Compliance, and Regulatory Risks

1. 20Our ability to market, distribute and sell our products in the U.S. and other countries may be adversely affected if our products fail to comply with the existing laws and regulations, and applicable requirements of the FDA, governmental agencies in other countries, and notified bodies
2. 21In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our future products under development or otherwise increase the costs associated with compliance
3. 22The aforementioned EU rules are generally applicable in the EEA. Non-compliance with the above requirements including as determined by a notified body would also prevent us from selling our products in these geographies
4. 23Any of these sanctions could adversely affect our business, financial condition and operating results
5. 24Actual or perceived failures to comply with foreign, federal, and state data privacy and security laws, regulations and standards may adversely affect our business, operations and financial performance
6. 25manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results
7. 26We are subject to certain fraud and abuse and transparency laws, which, if violated, could subject us to substantial penalties. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business
8. 27Healthcare regulation and reform measures could adversely affect our revenue and financial condition
9. 28which have issued or may issue in the future will be broad enough to prevent competitors from introducing similar devices, that such patents, if challenged, will be upheld by the courts or that we will be able to prove infringement and damages in litigation
10. 29If others choose to manufacture and sell products similar to or substantially the same as our products, it could have a material adverse effect on our business through loss of unit volume or price erosion, or both, and could adversely affect our ability to secure new business
11. 30Litigation, product liability claims or product recalls could be costly and could expose us to loss
12. 31Significant changes in U.S. trade, tax or other policies that restrict imports or increase import tariffs for certain countries, particularly Mexico, can escalate trade wars and could have a meaningful adverse effect on our results of operations
13. 32Our operations may be adversely impacted by our exposure to risks related to foreign currency exchange rates
14. 33International sales pose additional risks related to competition with larger international companies and established local companies and higher credit risk
15. 34We are dependent on manufacturing in Mexico, and could be adversely affected by that region's increased labor costs and any economic, social or political disruptions
16. 35We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and other worldwide anti-bribery laws
17. 36We are subject to risks associated with doing business outside of the U.S

Risks Related to our Strategic Transactions

1. 37relationships, our corporate culture could be undermined, the quality of our products and customer service could suffer, and our reputation could be harmed, each of which could adversely impact our business, financial condition and results of operations
2. 38If we are unable to effectively manage our internal growth or growth through acquisitions of companies, assets or products, our financial performance may be adversely affected
3. 39acquisition, which could adversely affect our business, including by restricting our ability to engage in additional transactions or incur additional indebtedness